Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PSMA PET-Positive Castration-Resistant Prostate Cancer”

6 trials

Showing 6 of 6 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298
What this trial is testing

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Who this might be right for
Prostatic Neoplasm
Novartis Pharmaceuticals 49
Large-scale testing (Phase 3)Looking for participantsNCT06520345
What this trial is testing

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 430
Not applicableStudy completedNCT06809426
What this trial is testing

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 13
Not applicableLooking for participantsNCT06850545
What this trial is testing

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital 150
Testing effectiveness (Phase 2)Looking for participantsNCT06549465
What this trial is testing

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics 60
Testing effectiveness (Phase 2)Study completedNCT03454750
What this trial is testing

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT Positive
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 143

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation